Shopping Cart
Remove All
Your shopping cart is currently empty
VU591
Copy Product Info
😃Good
Catalog No. T13320LCas No. 1222810-74-3
VU591 is a selective extra-renal potassium channel inhibitor with an IC₅₀ of 0.24 μM.
VU591
Copy Product Info😃Good
Purity: 99.53%
Catalog No. T13320LCas No. 1222810-74-3
VU591 is a selective extra-renal potassium channel inhibitor with an IC₅₀ of 0.24 μM.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $43 | In Stock | In Stock | |
| 10 mg | $73 | In Stock | In Stock | |
| 25 mg | $143 | In Stock | In Stock | |
| 50 mg | $256 | In Stock | In Stock | |
| 100 mg | $383 | In Stock | In Stock | |
| 500 mg | $822 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $47 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.53%
Appearance:Solid
Color:White to Yellow
Contact us for more batch information
Product Introduction
VU591 AI Summary
VU591 demonstrates diverse bioactivities across several targets. It exhibits potent inhibition of the ROMK S44D mutant and the ROMK1 potassium channel, with IC50 values ranging from 240.0 nM to approximately 794.33 nM in HEK293 cells, measured using a thallium efflux fluorescence assay. Additionally, it shows inhibitory activity against various channels and transporters, including hamster SUR1/mouse Kir6.2, GABA receptors, dopamine receptors (DRD4), dopamine transporters, and norepinephrine transporters at different concentrations. The compound also displays good protein binding affinity and moderate metabolic stability in both human and rat plasma and liver microsomes, respectively.
In the context of antiviral activity, VU591 inhibits SARS-CoV-2-induced cytotoxicity in Caco-2 and VERO-6 cells at a concentration of 10 µM, although the inhibition percentages vary. It also shows 6.246% inhibition of the SARS-CoV-2 3CL protease at 20 µM. Furthermore, the compound demonstrates activity against human HDAC6, with inhibition percentages recorded at -21.74% and -5.43% using enzymatic assays with different substrates.
Overall, VU591 is a multifaceted bioactive molecule with significant potential in potassium channel modulation, antiviral activity against SARS-CoV-2, and HDAC6 inhibition..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | VU591 is a selective extra-renal potassium channel inhibitor with an IC₅₀ of 0.24 μM. |
| Targets&IC50 | ROMK:0.24 μM |
| Molecular Weight | 368.3 |
| Formula | C16H12N6O5 |
| Cas No. | 1222810-74-3 |
| Smiles | [O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1 |
| Relative Density. | 1.641 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 3.69 mg/mL (10.02 mM), Sonication is recommended.  | ||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.72 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy VU591 | purchase VU591 | VU591 cost | order VU591 | VU591 chemical structure | VU591 formula | VU591 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.